Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

NCT07332338 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-03-23

No results posted yet for this study

Summary

REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.

Conditions

  • Post-COVID-19 Condition
  • Post-COVID Condition
  • Post-COVID Syndrome
  • Long COVID
  • Chronic Fatigue
  • Chronic Fatigue Symptoms
  • Fatigue Post Viral

Interventions

BIOLOGICAL

REGENECYTE®

HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)

Sponsors & Collaborators

  • StemCyte, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07332338 on ClinicalTrials.gov